Findings

For patients with gout, starting urate-lowering therapy with allopurinol does not appear to lead to an increased risk of developing stage 3 or higher chronic kidney disease (CKD), reports a study in JAMA Internal Medicine.

There is a “dearth of convincing evidence” that lipid-lowering treatment with statin drugs plays any major role in improving outcomes other than cardiovascular disease (CVD), concludes a review and meta-analysis in Annals of Internal Medicine.

Routine catheter replacement does not improve outcomes for hospitalized patients with catheter-associated urinary tract infection (UTI), according to a report in Journal of the American Geriatric Society.

In patients with acute kidney injury (AKI), treatment with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) is associated with a lower risk of death but an increased risk of kidney-related hospitalization, reports a study in JAMA Internal Medicine.

Rituximab appears more effective than tacrolimus in children with corticosteroid-dependent nephrotic syndrome (CDNS), reports a trial in JAMA Pediatrics.

Sulfonylureas are widely used as second-line oral antidiabetic therapy, despite potential cardiotoxicity and hypoglycemia risk. A new UK population-based cohort study suggests that such second-line treatment with sulfonylureas is associated with increased risks of myocardial infarction, death, and severe hypoglycemia. The study was published in the British Medical Journal.

/kidneynews/10_10_11/22/graphic/22f1.jpg

In patients with heart failure and renal impairment, the calcium sensitizer levosimendan is associated with improved kidney function, compared to no improvement with dobutamine, reports a randomized trial in the open-access Journal of the American Heart Association.

The α-adrenergic receptor blocker tamsulosin does not increase passage of small, symptomatic ureteral stones, reports a randomized clinical trial in JAMA Internal Medicine.

The two-phase trial included 512 adults seen in the emergency department with symptomatic ureteral stones. All patients had a symptomatic ureteral stone measuring less than 9 mm in diameter (mean 3.8 mm) on computed tomography. About three-fourths of patents were male and one-fourth were non-white; the mean age was 40.6 years.

A new kidney disease gene panel provides a comprehensive, cost-effective tool for genetic diagnosis of patients with cystic and glomerular inherited kidney diseases, reports a clinical investigation in Kidney International.

/kidneynews/10_9/14/graphic/14f1.jpg

A team-based CKD registry improves some clinical measures and care processes for patients in a safety-net primary care setting, reports a trial in the American Journal of Kidney Diseases.

Pages